Real Chemistry Acquires conversationHEALTH
Global health innovation company Real Chemistry announced the acquisition of conversationHEALTH, a conversational artificial intelligence (AI) platform for the health care and life sciences industry.
About Business Wire
This author has yet to write their bio.Meanwhile lets just say that we are proud Business Wire contributed a whooping 731 entries.
Entries by Business Wire
Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider Experience
Pear Therapeutics, Inc. has announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.
Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory LBCL
The U.S. Food and Drug Administration approved Gilead Company Kite’s Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
U.S. FDA Approves Cabenuva for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA as Well as Oral Factor XIa Inhibitor Program
Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.
FDA Approves Merck’s KEYTRUDA for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement
IQVIA announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity and increased ROI.
U.S. FDA approves LYNPARZA as adjuvant treatment for patients with gBRCAm HER2-negative high-risk early breast cancer
AstraZeneca and Merck & Co. Inc. announced Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States
LEO Pharma A/S, a global leader in medical dermatology, announced the appointment of Brian Hilberdink as Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.
HealthSTAR Communications is now Propel Health
HealthSTAR Communications, a 23-year independent network of health communications agencies and technology-enabled services, announced that the company rebranded and relaunched as Propel Health.